Switching patients with AMD from ranibizumab or aflibercept to faricimab
A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMD
This study is testing if switching people with age-related macular degeneration from their current eye injections to a new treatment called faricimab can improve their vision and reduce the number of injections they need.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Drugs / interventions | ranibizumab, Faricimab |
| Locations | 1 site (Nantes) |
| Trial ID | NCT06271330 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the real-life effectiveness of switching patients with age-related macular degeneration (AMD) from existing anti-VEGF treatments, ranibizumab or aflibercept, to a new treatment option, faricimab. Faricimab is a bi-specific monoclonal antibody that targets both VEGF-A and ANG2, potentially allowing for longer intervals between injections compared to previous therapies. The study will include patients who have been treated with anti-VEGF for over a year and have injection intervals of less than 12 weeks. The goal is to assess the benefits of this switch in a practical setting, reflecting everyday clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with exudative AMD who have been treated with ranibizumab or aflibercept for more than a year.
Not a fit: Patients with severe myopia, certain retinal conditions, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide patients with AMD a more effective treatment option that requires fewer injections.
How similar studies have performed: Other studies have shown promising results with similar approaches, but this specific switch to faricimab is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patient of legal age (≥18 years) with exudative AMD treated with IVT ranibizumab or aflibercept \> 1 year. * Patient whose IVT injection interval is strictly less than 12 weeks. Exclusion Criteria: * Severe myopia (axial length \> 26 mm or sphere \< - 6 dioptres). * Presence of angioid striae. * Presence of moderate or more severe diabetic retinopathy. * History of diabetic macular edema. * History of uveitis. * Previous retinal vein occlusion (branch or central vein). * History of pseudovitelliform macular dystrophy. * Patient under guardianship or trusteeship * Pregnant or breast-feeding woman
Where this trial is running
Nantes
- Ducloyer — Nantes, France (Recruiting)
Study contacts
- Principal investigator: Jean-Baptiste Ducloyer, M.D — Nantes University Hospital
- Study coordinator: Jean-Baptiste Ducloyer, M.D
- Email: jeanbaptiste.ducloyer@chu-nantes.fr
- Phone: 02 40 08 34 01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.